Abstract:Wnt proteins modulate cell proliferation and differentiation and the self-renewal of stem cells by inducing β-catenin-dependent signalling through the Wnt receptor frizzled (FZD) and the co-receptors LRP5 and LRP6 to regulate cell fate decisions and the growth and repair of several tissues. The 19 mammalian Wnt proteins are cross-reactive with the 10 FZD receptors, and this has complicated the attribution of distinct biological functions to specific FZD and Wnt subtype interactions. Furthermore, Wnt proteins are modified post-translationally by palmitoylation, which is essential for their secretion, function and interaction with FZD receptors. As a result of their acylation, Wnt proteins are very hydrophobic and require detergents for purification, which presents major obstacles to the preparation and application of recombinant Wnt proteins. This hydrophobicity has hindered the determination of the molecular mechanisms of Wnt signalling activation and the functional importance of FZD subtypes, and the use of Wnt proteins as therapeutic agents. Here we develop surrogate Wnt agonists, water-soluble FZD-LRP5/LRP6 heterodimerizers, with FZD5/FZD8-specific and broadly FZD-reactive binding domains. Similar to WNT3A, these Wnt agonists elicit a characteristic β-catenin signalling response in a FZD-selective fashion, enhance the osteogenic lineage commitment of primary mouse and human mesenchymal stem cells, and support the growth of a broad range of primary human organoid cultures. In addition, the surrogates can be systemically expressed and exhibit Wnt activity in vivo in the mouse liver, regulating metabolic liver zonation and promoting hepatocyte proliferation, resulting in hepatomegaly. These surrogates demonstrate that canonical Wnt signalling can be activated by bi-specific ligands that induce receptor heterodimerization. Furthermore, these easily produced, non-lipidated Wnt surrogate agonists facilitate functional studies of Wnt signalling and the exploration of Wnt agonists for translational applications in regenerative medicine.

Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling

Wnt Signaling:Essential Roles in Osteoblast Differentiation,bone Metabolism and Therapeutic Implications for Bone and Skeletal Disorders

Synthetic Frizzled agonist and LRP antagonist for high-efficiency Wnt/β-catenin signaling manipulation in organoid cultures and in vivo

Modulating the wnt signaling pathway with small molecules

Structure-guided Design Fine-Tunes Pharmacokinetics, Tolerability, and Antitumor Profile of Multispecific Frizzled Antibodies

Small Molecule–mediated Disruption of Wnt-dependent Signaling in Tissue Regeneration and Cancer

Development of selective bispecific Wnt mimetics for bone loss and repair

Wnt proteins are lipid-modified and can act as stem cell growth factors

Progress in the Development of Modulators Targeting Frizzleds

Small Activating RNA Modulation of the G Protein‐Coupled Receptor for Cancer Treatment

Drugging a Stem Cell Compartment Using Wnt3a Protein As a Therapeutic.

LRP5/6 Directly Bind to Frizzled and Prevent Frizzled-regulated Tumour Metastasis.

Synthetic Presentation of Noncanonical Wnt5a Motif Promotes Mechanosensing-Dependent Differentiation of Stem Cells and Regeneration.

Immobilization of Wnt Fragment Peptides on Magnetic Nanoparticles or Synthetic Surfaces Regulate Wnt Signaling Kinetics

Design, Synthesis, and Evaluation of Potent Wnt Signaling Inhibitors Featuring a Fused 3-Ring System.

In Vivo And In Vitro Models For The Therapeutic Targeting Of Wnt Signaling Using A Tet-O Delta N89 Beta-Catenin System

In situ Fucosylation for Modulating Wnt Signaling in Live Cells

Effects of Fc Glycosylation on the Activity of WNT Mimetic Agonistic Antibodies.

Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer

The recent progress of peptide regulators for the Wnt/-catenin signaling pathway

Manipulation of focal Wnt activity via synthetic cells in a double-humanized zebrafish model of tumorigenesis